Watch Latest Interview
OUR COMPANY
PharmAust is a clinical-stage biotechnology company developing new therapeutics for human health. The company is repurposing monepantel for the treatment of neurodegenerative diseases, starting with amyotrophic lateral sclerosis which is the most common form of motor neurone disease.
OUR SCIENCE
In mammalian cells, monepantel is a potent inhibitor of the mTOR pathway. The mTOR pathway plays a central role in cell growth and proliferation, and in degenerating neurons.